654-97-7

Usage

Uses

Used in Pharmaceutical Industry:
5-bromo-2-trifluoromethylbenzoic acid is used as a chemical intermediate for the synthesis of pharmaceutical compounds. Its unique combination of functional groups allows for the creation of a variety of drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
5-bromo-2-trifluoromethylbenzoic acid is used as a precursor in the production of agrochemicals. Its reactivity and functional groups contribute to the development of new compounds that can be used in agricultural settings to control pests and diseases.
Used in Organic Synthesis:
5-bromo-2-trifluoromethylbenzoic acid is used as a building block in the synthesis of other organic compounds. Its aromatic structure and electron-withdrawing and electron-donating substituents enable it to participate in a wide range of chemical reactions, making it a valuable component in the synthesis of various organic molecules.

Upstream product

• 842136-32-7 5-bromo-2-trifluoromethylbenzoic acid methyl ester 
• 610-71-9 2,5-dibromobenzoic acid 
• 77152-08-0 trifluoromethylcopper(I) 
• 181765-86-6 5-bromo-2-iodo-benzoic acid methyl ester 
• 21740-00-1 5-bromo-2-iodo-benzoic acid 

Downstream Products

• 1214349-47-9 C₈H₃BrClF₃O 
• 1548-16-9 5-bromo-2-(trifluoromethyl)benzamide 

Relevant academic research and scientific papers

ETHYNYL COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE FOR THE TREATMENT OF MALARIA

The present disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein R1 means a fluorine atom or a perhalogeno linear alkyl radical containing 1, 2 or 3 carbon atoms; R2 means a chlorine atom, a linear alkyl radical containing 1, 2 or 3 carbon atoms or a perhalogeno linear alkyl radical containing 1, 2 or 3 carbon atoms, and R means a hydrogen atom or a radical of formula (la). The present disclosure also relates to processes for their preparation as well their therapeutic uses, in particular such as for use in the treatment of malaria.

Trifluoromethylation of aryl and heteroaryl halides with fluoroform-derived CuCF3: Scope, limitations, and mechanistic features

Fluoroform-derived CuCF3 recently discovered in our group exhibits remarkably high reactivity toward aryl and heteroaryl halides, performing best in the absence of extra ligands. A broad variety of iodoarenes undergo smooth trifluoromethylation with the ligandless CuCF3 at 23-50 C to give the corresponding benzotrifluorides in nearly quantitative yield. A number of much less reactive aromatic bromides also have been trifluoromethylated, including pyridine, pyrimidine, pyrazine, and thiazole derivatives as well as aryl bromides bearing electron-withdrawing groups and/or ortho substituents. Only the most electrophilic chloroarenes can be trifluoromethylated, e.g., 2-chloronicotinic acid. Exceptionally high chemoselectivity of the reactions (no side-formation of arenes, biaryls, and C2F5 derivatives) has allowed for the isolation of a large number of trifluoromethylated products in high yield on a gram scale (up to 20 mmol). The CuCF3 reagent is destabilized by CuX coproduced in the reaction, the magnitude of the effect paralleling the Lewis acidity of CuX: CuCl > CuBr > CuI. While SNAr and SRN1 mechanisms are not operational, there is a well-pronounced ortho effect, i.e., the enhanced reactivity of ortho-substituted aryl halides 2-RC6H4X toward CuCF3. Intriguingly, this ortho-effect is observed for R = NO2, COOH, CHO, COOEt, COCH3, OCH3, and even CH3, but not for R = CN. The fluoroform-derived CuCF3 reagent and its reactions with haloarenes provide an unmatched combination of reactivity, selectivity, and low cost.

PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH

Provided herein are Pyrazole Pyrazine Amine Compounds having the following structure:Formula (I). Wherein Q and R1-R3 are as defined herein, compositions comprising an effective amount of a Pyrazole Pyrazine Amine Compound and methods for treating or preventing inflammatory conditions, immunological conditions, cancer, neurodegenerative diseases, age-related diseases, cardiovascular diseases and metabolic conditions, or conditions treatable or preventable by inhibition of an IKK, or an IKK pathway, comprising administering an effective amount of a Pyrazole Pyrazine Amine Compound to a patient in need thereof.